JRoon71
6 minutes ago
We also have to remember, IPE is such a tiny component of each of the generic company's drug portfolios, that they may just eat the cost in the short-term if they cannot exit or modify a contract due to the tariffs. They can re-negotiate price at year-end or contract end.
Or, it's als